evorpacept

Evorpacept is a recombinant fusion protein and immunotherapy agent designed to block the CD47–SIRPα pathway, which is a key immune checkpoint exploited by cancer cells to evade phagocytosis. By binding with high affinity to CD47 on tumor cells, evorpacept prevents its interaction with SIRPα on phagocytic cells (such as macrophages and dendritic cells), thereby abrogating the "don't eat me" signal that inhibits immune-mediated clearance of cancer cells[1][2][3]. This blockade enhances macrophage-mediated phagocytosis, stimulates dendritic cell activity, promotes T-cell activation through cross-priming, and can improve the efficacy of other anti-cancer therapies including monoclonal antibodies, antibody-drug conjugates (ADCs), and checkpoint inhibitors[2][5][6]. Evorpacept has demonstrated a favorable safety profile in clinical trials compared to earlier anti-CD47 agents due to its engineered inactive Fc domain[6]. It is being developed primarily for various solid tumors and hematologic malignancies by ALX Oncology in collaboration with several partners.

Other names

evorpacept